GSTM1 and anemia (phenotype): In addition, earlier studies suggested low baseline Hb level, early decrease in Hb level after treatment, cumulative platinum dose, advanced age, lack of chemotherapeutic response, and high residual platinum levels after administration as risk factors for platinum‐associated anaemia.31, 34